| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Bormann-Kennedy Barbara-Jean Anne serves as a Director at XERS. Across recent SEC filings that breaks down to 0 buys and 1 sell. Those positions are worth an estimated $1.2M at current prices.
The biggest single holding is XERS (~$1.2M) as Director. The recent filings there lean toward selling, a net 15,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | XERS Xeris Biopharma Holdings, Inc. | Director | Sell | 15,000 | $7.09 | $106,414.50 | -9.5% | -23.6% | - |